Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Change in Acquisitions & Divestments (2016 - 2025)

Ligand Pharmaceuticals' Change in Acquisitions & Divestments history spans 15 years, with the latest figure at $179.1 million for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments fell 11.17% year-over-year to $179.1 million; the TTM value through Dec 2025 reached $217.7 million, down 5.09%, while the annual FY2025 figure was $217.7 million, 5.09% down from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was $179.1 million at Ligand Pharmaceuticals, up from $185000.0 in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $201.6 million in Q4 2024 and bottomed at -$85.4 million in Q4 2021.
  • The 5-year median for Change in Acquisitions & Divestments is $24.8 million (2022), against an average of $40.5 million.
  • The largest annual shift saw Change in Acquisitions & Divestments soared 9681.07% in 2022 before it crashed 183.65% in 2024.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at -$85.4 million in 2021, then skyrocketed by 108.21% to $7.0 million in 2022, then grew by 6.45% to $7.5 million in 2023, then skyrocketed by 2602.27% to $201.6 million in 2024, then fell by 11.17% to $179.1 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Change in Acquisitions & Divestments are $179.1 million (Q4 2025), $185000.0 (Q3 2025), and $6.1 million (Q2 2025).